Thoratec Presentation At Canaccord Genuity Growth Conference To Be Webcast

00:50 EDT 17 Sep 2017 | PR Newswire

PLEASANTON, Calif., Aug. 4, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13.

Taylor C. Harris, Vice President and Chief Financial Officer, will provide an update on the company, beginning at 2:00 p.m., Eastern Daylight Time (11:00 a.m., Pacific Daylight Time).  

A webcast of the presentation will be available at, or on the company's website at

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate II® and HeartMate III™ LVAS (Left Ventricular Assist Systems) and Thoratec® VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag® and PediMag®/PediVAS®, and HeartMate PHP™ product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's website at

Thoratec, the Thoratec logo, HeartMate, HeartMate II, and HeartMate III are registered trademarks of Thoratec Corporation and HeartMate III, HeartMate PHP, and IVAD are trademarks of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH.

SOURCE Thoratec Corporation


More From BioPortfolio on "Thoratec Presentation At Canaccord Genuity Growth Conference To Be Webcast"

Quick Search